Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 3:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ustekinumab 45 mg Clear all
Completed Phase 3 Interventional Results available

An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age

NCT02698475
View directory record Official record
Conditions
Psoriasis
Interventions
Ustekinumab 0.75 mg/kg, Ustekinumab 45 mg, Ustekinumab 90 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
6 Years to 11 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
7
States / cities
San Diego, California • Chicago, Illinois • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 24, 2026, 3:54 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis

NCT01009086
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
615 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
26
States / cities
Encinitas, California • La Jolla, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2015 · Synced Sep 24, 2026, 3:54 AM EDT
Completed Phase 1Phase 2 Interventional

Ustekinumab (Anti-IL-12/23p40 Monoclonal Antibody) in Patients With Leukocyte Adhesion Deficiency Type 1 (LAD1) Who Have Inflammatory Pathology

NCT03366142
View directory record Official record
Conditions
LAD1
Interventions
Ustekinumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Sep 24, 2026, 3:54 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis

NCT02074982
View directory record Official record
Conditions
Chronic Plaque Type Psoriasis
Interventions
AIN457 300 mg, ustekinumab 45/90 mg, placebo secukinumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
676 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
26
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 24, 2026, 3:54 AM EDT
Completed Phase 2 Interventional Results available

A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid

NCT01389973
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
ustekinumab 90 mg, ustekinumab 45 mg, ustekinumab 180 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Jacksonville, Florida • Miami, Florida • Naples, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2016 · Synced Sep 24, 2026, 3:54 AM EDT
Completed Phase 2 Interventional Results available

Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease

NCT01713400
View directory record Official record
Conditions
Graft vs. Host Disease
Interventions
Ustekinumab, Placebo, Tacrolimus (TAC), Sirolimus
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Sep 24, 2026, 3:54 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis

NCT02438787
View directory record Official record
Conditions
Axial Spondyloarthritis
Interventions
Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg, Golimumab 50 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
19
States / cities
Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 24, 2026, 3:54 AM EDT
Completed Phase 3 Interventional Results available

Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis

NCT02826603
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Secukinumab, Ustekinumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
123
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 103 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2019 · Synced Sep 24, 2026, 3:54 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)

NCT02319759
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Guselkumab, Ustekinumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
12
States / cities
Huntsville, Alabama • Trumbull, Connecticut • Clearwater, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 24, 2026, 3:54 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris

NCT01999868
View directory record Official record
Conditions
Psoriasis
Interventions
Ustekinumab, Abatacept, UST Placebo, ABA Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
8
States / cities
Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Sep 24, 2026, 3:54 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects

NCT01708629
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
210 mg brodalumab, 140 mg brodalumab, ustekinumab, placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,881 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
74
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Sep 24, 2026, 3:54 AM EDT
Completed Phase 3 Interventional Results available

Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis

NCT05335356
View directory record Official record
Conditions
Moderate to Severe Chronic Plaque Psoriasis
Interventions
Stelara, Bmab1200
Biological
Lead sponsor
Biocon Biologics UK Ltd
Industry
Eligibility
18 Years to 80 Years
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Mayfield Heights, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Sep 24, 2026, 3:54 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis

NCT02437162
View directory record Official record
Conditions
Axial Spondyloarthritis
Interventions
Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg, Golimumab 50 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
11
States / cities
Peoria, Arizona • St. Petersburg, Florida • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 24, 2026, 3:54 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents

NCT01077362
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
placebo, ustekinumab 45 mg, ustekinumab 90 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
25
States / cities
Birmingham, Alabama • Huntsville, Alabama • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2014 · Synced Sep 24, 2026, 3:54 AM EDT
Completed Phase 3 Interventional Results available

A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis

NCT00267969
View directory record Official record
Conditions
Psoriasis
Interventions
ustekinumab, placebo
Drug
Lead sponsor
Centocor Research & Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
766 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
28
States / cities
Phoenix, Arizona • Los Angeles, California • Redwood City, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2013 · Synced Sep 24, 2026, 3:54 AM EDT
Completed Phase 3 Interventional Results available

A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis

NCT01550744
View directory record Official record
Conditions
Psoriasis
Interventions
Ustekinumab 45 mg, Ustekinumab 90 mg, Placebo
Drug
Lead sponsor
Janssen Biotech, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
40
States / cities
Birmingham, Alabama • Bakersfield, California • Irvine, California + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Sep 24, 2026, 3:54 AM EDT
Terminated Phase 3 Interventional Results available

P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis

NCT01708603
View directory record Official record
Conditions
Moderate to Severe Plaque Psoriasis
Interventions
210 mg brodalumab, 140 mg brodalumab, ustekinumab, placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,831 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
67
States / cities
Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2020 · Synced Sep 24, 2026, 3:54 AM EDT
Completed Phase 3 Interventional Results available

A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab

NCT02203032
View directory record Official record
Conditions
Psoriasis
Interventions
Ustekinumab, Guselkumab, Placebo for ustekinumab, Placebo for guselkumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
872 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
29
States / cities
Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Sep 24, 2026, 3:54 AM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

NCT04607980
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
ABP 654, Ustekinumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
563 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
34
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 30 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Sep 24, 2026, 3:54 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis

NCT00307437
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg, Ustekinumab (CNTO 1275) 45 mg, Ustekinumab (CNTO 1275) 90 mg
Drug
Lead sponsor
Centocor Research & Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
28
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Sep 24, 2026, 3:54 AM EDT